Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06102018
Collaborator
(none)
150
1
24.3
6.2

Study Details

Study Description

Brief Summary

The goal of this observational study is to find the diagnostic biomarkers in serum and urine from early breast cancer patients. The main questions it aims to answer are:

  • compare the different biomarkers in serum and urine from breast cancer patients, benign lesions and healthy population.

  • construct the best diagnostic model by machine learning to distinguish breast cancer and non-breast cancer patients.

Participants, including breast and non-breast cancer patients will be asked to provides blood and urine during their diagnosis and treatment process without changing the original treatment. When necessary, specimens will be collected during the surgery,without affecting pathological diagnosis.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Collect blood and urine,pathological specimens if necessary

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Biomarkers Exploration of Breast Cancer From Serum and Urine
Actual Study Start Date :
Jun 22, 2022
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Breast cancer patients

No intervention. The patients who are diagnosed as breast cancer by postoperative pathological.

Diagnostic Test: Collect blood and urine,pathological specimens if necessary
Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube

Patients with benign breast lesions

No intervention. The patients who are diagnosed asbenign breast lesions by postoperative pathological.

Diagnostic Test: Collect blood and urine,pathological specimens if necessary
Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube

Healthy population

No intervention. The volunteers.

Diagnostic Test: Collect blood and urine,pathological specimens if necessary
Use EDTA anticoagulant pipe to collect all blood 2ml, and collect 3ml of urine with sterile test tube

Outcome Measures

Primary Outcome Measures

  1. The different biomarkers in malignant and benign breast diseases [It is expected to be one to two years.]

    By analyzing the differences (eg:PCA, FC and et al.)in the composition of proteins in blood and urine, biomarkers with significant differences between the two groups will be obtained.

  2. Diagnostic models used different biomarkers by machine learning [Within half a year after the completion of the test.]

    Using biomarkers that detect discrepancies, combined with machine learning to build early breast cancer diagnostic models.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Signing the consent of informedness;

  2. Patients with breast mass who need surgery after examination;

  3. Cardiac ultrasound indicates that the blood score of the heart is within the normal range;

  4. ECOG≤0-2 points;

  5. Oversure function is acceptable.

Exclusion Criteria:
  1. Merge other malignant tumors such as gynecologic oncology;

  2. After evaluation, the internal organs are not suitable.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Guangzhou Guangdong China 510120

Sponsors and Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT06102018
Other Study ID Numbers:
  • SYSKY-2022-149-02
First Posted:
Oct 26, 2023
Last Update Posted:
Oct 26, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 26, 2023